Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

Matthew D. Linnik; Jay Z. Hu; Kenneth R. Heilbrunn; Vibeke Strand; Frank L. Hurley; Tenshang Joh; D. Alarcón-Segovia; G. Appel; C. Aranow; S. Ballou; M. A. Becker; N. Becker; M. H. Belmont; A. Bohan; E. P. Boling; S. Bombardieri; W. G. Brelsford; J. P. Buyon; M. H. Cardiel; N. L. Carteron; J. J. Condemi; M. E. Cronin; J. J. Cush; R. DeHoratius; D. Desir; M. Edwards; M. A. El-Shahawy; P. Emery; L. R. Espinoza; T. H. Finkel; M. Fondal; P. Fortin; R. A. Furie; M. C. Genovese; T. Geppert; A. Gil-Aguado; G. S. Gilkeson; E. Ginzler; O. S. Gluck; J. L. Granda; J. Grossman; F. Hiepe; M. Hill; P. Howard; C. Hura; M. Ingelmo; A. Jaffer; J. Jakes; J. P. Kalden; K. C. Kalunian; G. M. Kammer; K. Kanick; J. Kaplan; S. Kaplan; R. Katz; H. M. Kenney; M. Khamashta; A. J. Kivitz; M. Krishnan; N. A. Kurtzman; M. Liebling; J. S. Lindberg; S. H. Lourie; J. Loveless; S. Manzi; K. Martin; J. McKay; J. Merrill; L. W. Moreland; M. C. Neuwelt; M. Petri; B. C. Poque; R. J. Quinet; R. Ramsey-Goldman; S. G. Rosenblatt; N. Rothfield; N. Scarpa; M. Schneider; J. T. Schousboe; L. K. Sewell; W. J. Shergy; Y. Sherrer; J. Sibilia; D. Smith; B. Spinowitz; M. Spira; R. Staud; S. Stern; M. P. Stevens; G. Sturfelt; W. Surbeck; E. A. Tindall; A. Torres; J. Tumlin; R. Van Vollenhoven; J. Varga; A. Vijayan; M. Vilardell-Tarres; D. Wallace; C. Weaver; M. Zummer

doi:10.1002/art.20980

Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

Matthew D. Linnik, Jay Z. Hu, Kenneth R. Heilbrunn, Vibeke Strand, Frank L. Hurley, Tenshang Joh, D. Alarcón-Segovia, G. Appel, C. Aranow, S. Ballou, M. A. Becker, N. Becker, M. H. Belmont, A. Bohan, E. P. Boling, S. Bombardieri, W. G. Brelsford, J. P. Buyon, M. H. Cardiel, N. L. CarteronJ. J. Condemi, M. E. Cronin, J. J. Cush, R. DeHoratius, D. Desir, M. Edwards, M. A. El-Shahawy, P. Emery, L. R. Espinoza, T. H. Finkel, M. Fondal, P. Fortin, R. A. Furie, M. C. Genovese, T. Geppert, A. Gil-Aguado, G. S. Gilkeson, E. Ginzler, O. S. Gluck, J. L. Granda, J. Grossman, F. Hiepe, M. Hill, P. Howard, C. Hura, M. Ingelmo, A. Jaffer, J. Jakes, J. P. Kalden, K. C. Kalunian, G. M. Kammer, K. Kanick, J. Kaplan, S. Kaplan, R. Katz, H. M. Kenney, M. Khamashta, A. J. Kivitz, M. Krishnan, N. A. Kurtzman, M. Liebling, J. S. Lindberg, S. H. Lourie, J. Loveless, S. Manzi, K. Martin, J. McKay, J. Merrill, L. W. Moreland, M. C. Neuwelt, M. Petri, B. C. Poque, R. J. Quinet, R. Ramsey-Goldman, S. G. Rosenblatt, N. Rothfield, N. Scarpa, M. Schneider, J. T. Schousboe, L. K. Sewell, W. J. Shergy, Y. Sherrer, J. Sibilia, D. Smith, B. Spinowitz, M. Spira, R. Staud, S. Stern, M. P. Stevens, G. Sturfelt, W. Surbeck, E. A. Tindall, A. Torres, J. Tumlin, R. Van Vollenhoven, J. Varga, A. Vijayan, M. Vilardell-Tarres, D. Wallace, C. Weaver, M. Zummer

Research output: Contribution to journal › Article › peer-review

199 Scopus citations

Abstract

Objective. To examine the relationship between changes in anti-double-stranded DNA (anti-dsDNA) antibody levels and the risk of renal flare in patients with systemic lupus erythematosus (SLE), using data from 2 randomized, controlled trials. Methods. Analyses were based on 487 patients with SLE and a history of lupus nephritis who had an anti-dsDNA antibody titer ≥15 IU/ml at baseline, as measured by Farr assay. Results are presented for the combined population of patients, the placebo arms, and the drug treatment arms in which a dsDNA-based bioconjugate (abetimus sodium; LJP 394) was used. Results. Changes in anti-dsDNA antibody levels were inversely correlated with changes in the C3 level (P < 0.0001 in both trials). Cox proportional hazards regression models showed that changes in anti-dsDNA antibody levels correlated with the risk of renal flare. The models predicted that a point estimate of a 50% reduction in anti-dsDNA antibody levels is associated with a 52% reduction (95% confidence interval [95% CI] 26-68%, nominal P = 0.0007) and a 53% reduction (95% CI 33-69%, nominal P < 0.0001) in the risk of renal flare in the 2 trials, respectively. In the 2 trials, the incidence of renal flare was lower in patients with sustained reductions in anti-dsDNA antibodies (3.0% and 4.1%, respectively) than in patients with stable or increasing antibody levels (21.3% and 20.3%, respectively). Conclusion. Changes in anti-dsDNA antibody levels were directly correlated with the risk of renal flare and inversely correlated with changes in the C3 level. Reducing anti-dsDNA antibody levels may represent a therapeutic objective in SLE patients with lupus nephritis, because it is associated with a reduced risk of renal flare.

Original language	English
Pages (from-to)	1129-1137
Number of pages	9
Journal	Arthritis and rheumatism
Volume	52
Issue number	4
DOIs	https://doi.org/10.1002/art.20980
State	Published - Apr 2005

Access to Document

10.1002/art.20980

Cite this

Linnik, M. D., Hu, J. Z., Heilbrunn, K. R., Strand, V., Hurley, F. L., Joh, T., Alarcón-Segovia, D., Appel, G., Aranow, C., Ballou, S., Becker, M. A., Becker, N., Belmont, M. H., Bohan, A., Boling, E. P., Bombardieri, S., Brelsford, W. G., Buyon, J. P., Cardiel, M. H., ... Zummer, M. (2005). Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis and rheumatism, 52(4), 1129-1137. https://doi.org/10.1002/art.20980

@article{47ade4d55bf14718be2ae84d51f42112,

title = "Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus",

abstract = "Objective. To examine the relationship between changes in anti-double-stranded DNA (anti-dsDNA) antibody levels and the risk of renal flare in patients with systemic lupus erythematosus (SLE), using data from 2 randomized, controlled trials. Methods. Analyses were based on 487 patients with SLE and a history of lupus nephritis who had an anti-dsDNA antibody titer ≥15 IU/ml at baseline, as measured by Farr assay. Results are presented for the combined population of patients, the placebo arms, and the drug treatment arms in which a dsDNA-based bioconjugate (abetimus sodium; LJP 394) was used. Results. Changes in anti-dsDNA antibody levels were inversely correlated with changes in the C3 level (P < 0.0001 in both trials). Cox proportional hazards regression models showed that changes in anti-dsDNA antibody levels correlated with the risk of renal flare. The models predicted that a point estimate of a 50% reduction in anti-dsDNA antibody levels is associated with a 52% reduction (95% confidence interval [95% CI] 26-68%, nominal P = 0.0007) and a 53% reduction (95% CI 33-69%, nominal P < 0.0001) in the risk of renal flare in the 2 trials, respectively. In the 2 trials, the incidence of renal flare was lower in patients with sustained reductions in anti-dsDNA antibodies (3.0% and 4.1%, respectively) than in patients with stable or increasing antibody levels (21.3% and 20.3%, respectively). Conclusion. Changes in anti-dsDNA antibody levels were directly correlated with the risk of renal flare and inversely correlated with changes in the C3 level. Reducing anti-dsDNA antibody levels may represent a therapeutic objective in SLE patients with lupus nephritis, because it is associated with a reduced risk of renal flare.",

author = "Linnik, {Matthew D.} and Hu, {Jay Z.} and Heilbrunn, {Kenneth R.} and Vibeke Strand and Hurley, {Frank L.} and Tenshang Joh and D. Alarc{\'o}n-Segovia and G. Appel and C. Aranow and S. Ballou and Becker, {M. A.} and N. Becker and Belmont, {M. H.} and A. Bohan and Boling, {E. P.} and S. Bombardieri and Brelsford, {W. G.} and Buyon, {J. P.} and Cardiel, {M. H.} and Carteron, {N. L.} and Condemi, {J. J.} and Cronin, {M. E.} and Cush, {J. J.} and R. DeHoratius and D. Desir and M. Edwards and El-Shahawy, {M. A.} and P. Emery and Espinoza, {L. R.} and Finkel, {T. H.} and M. Fondal and P. Fortin and Furie, {R. A.} and Genovese, {M. C.} and T. Geppert and A. Gil-Aguado and Gilkeson, {G. S.} and E. Ginzler and Gluck, {O. S.} and Granda, {J. L.} and J. Grossman and F. Hiepe and M. Hill and P. Howard and C. Hura and M. Ingelmo and A. Jaffer and J. Jakes and Kalden, {J. P.} and Kalunian, {K. C.} and Kammer, {G. M.} and K. Kanick and J. Kaplan and S. Kaplan and R. Katz and Kenney, {H. M.} and M. Khamashta and Kivitz, {A. J.} and M. Krishnan and Kurtzman, {N. A.} and M. Liebling and Lindberg, {J. S.} and Lourie, {S. H.} and J. Loveless and S. Manzi and K. Martin and J. McKay and J. Merrill and Moreland, {L. W.} and Neuwelt, {M. C.} and M. Petri and Poque, {B. C.} and Quinet, {R. J.} and R. Ramsey-Goldman and Rosenblatt, {S. G.} and N. Rothfield and N. Scarpa and M. Schneider and Schousboe, {J. T.} and Sewell, {L. K.} and Shergy, {W. J.} and Y. Sherrer and J. Sibilia and D. Smith and B. Spinowitz and M. Spira and R. Staud and S. Stern and Stevens, {M. P.} and G. Sturfelt and W. Surbeck and Tindall, {E. A.} and A. Torres and J. Tumlin and {Van Vollenhoven}, R. and J. Varga and A. Vijayan and M. Vilardell-Tarres and D. Wallace and C. Weaver and M. Zummer",

year = "2005",

month = apr,

doi = "10.1002/art.20980",

language = "English",

volume = "52",

pages = "1129--1137",

journal = "Arthritis and rheumatism",

issn = "0004-3591",

number = "4",

}

Linnik, MD, Hu, JZ, Heilbrunn, KR, Strand, V, Hurley, FL, Joh, T, Alarcón-Segovia, D, Appel, G, Aranow, C, Ballou, S, Becker, MA, Becker, N, Belmont, MH, Bohan, A, Boling, EP, Bombardieri, S, Brelsford, WG, Buyon, JP, Cardiel, MH, Carteron, NL, Condemi, JJ, Cronin, ME, Cush, JJ, DeHoratius, R, Desir, D, Edwards, M, El-Shahawy, MA, Emery, P, Espinoza, LR, Finkel, TH, Fondal, M, Fortin, P, Furie, RA, Genovese, MC, Geppert, T, Gil-Aguado, A, Gilkeson, GS, Ginzler, E, Gluck, OS, Granda, JL, Grossman, J, Hiepe, F, Hill, M, Howard, P, Hura, C, Ingelmo, M, Jaffer, A, Jakes, J, Kalden, JP, Kalunian, KC, Kammer, GM, Kanick, K, Kaplan, J, Kaplan, S, Katz, R, Kenney, HM, Khamashta, M, Kivitz, AJ, Krishnan, M, Kurtzman, NA, Liebling, M, Lindberg, JS, Lourie, SH, Loveless, J, Manzi, S, Martin, K, McKay, J, Merrill, J, Moreland, LW, Neuwelt, MC, Petri, M, Poque, BC, Quinet, RJ, Ramsey-Goldman, R, Rosenblatt, SG, Rothfield, N, Scarpa, N, Schneider, M, Schousboe, JT, Sewell, LK, Shergy, WJ, Sherrer, Y, Sibilia, J, Smith, D, Spinowitz, B, Spira, M, Staud, R, Stern, S, Stevens, MP, Sturfelt, G, Surbeck, W, Tindall, EA, Torres, A, Tumlin, J, Van Vollenhoven, R, Varga, J, Vijayan, A, Vilardell-Tarres, M, Wallace, D, Weaver, C & Zummer, M 2005, 'Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus', Arthritis and rheumatism, vol. 52, no. 4, pp. 1129-1137. https://doi.org/10.1002/art.20980

TY - JOUR

T1 - Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

AU - Linnik, Matthew D.

AU - Hu, Jay Z.

AU - Heilbrunn, Kenneth R.

AU - Strand, Vibeke

AU - Hurley, Frank L.

AU - Joh, Tenshang

AU - Alarcón-Segovia, D.

AU - Appel, G.

AU - Aranow, C.

AU - Ballou, S.

AU - Becker, M. A.

AU - Becker, N.

AU - Belmont, M. H.

AU - Bohan, A.

AU - Boling, E. P.

AU - Bombardieri, S.

AU - Brelsford, W. G.

AU - Buyon, J. P.

AU - Cardiel, M. H.

AU - Carteron, N. L.

AU - Condemi, J. J.

AU - Cronin, M. E.

AU - Cush, J. J.

AU - DeHoratius, R.

AU - Desir, D.

AU - Edwards, M.

AU - El-Shahawy, M. A.

AU - Emery, P.

AU - Espinoza, L. R.

AU - Finkel, T. H.

AU - Fondal, M.

AU - Fortin, P.

AU - Furie, R. A.

AU - Genovese, M. C.

AU - Geppert, T.

AU - Gil-Aguado, A.

AU - Gilkeson, G. S.

AU - Ginzler, E.

AU - Gluck, O. S.

AU - Granda, J. L.

AU - Grossman, J.

AU - Hiepe, F.

AU - Hill, M.

AU - Howard, P.

AU - Hura, C.

AU - Ingelmo, M.

AU - Jaffer, A.

AU - Jakes, J.

AU - Kalden, J. P.

AU - Kalunian, K. C.

AU - Kammer, G. M.

AU - Kanick, K.

AU - Kaplan, J.

AU - Kaplan, S.

AU - Katz, R.

AU - Kenney, H. M.

AU - Khamashta, M.

AU - Kivitz, A. J.

AU - Krishnan, M.

AU - Kurtzman, N. A.

AU - Liebling, M.

AU - Lindberg, J. S.

AU - Lourie, S. H.

AU - Loveless, J.

AU - Manzi, S.

AU - Martin, K.

AU - McKay, J.

AU - Merrill, J.

AU - Moreland, L. W.

AU - Neuwelt, M. C.

AU - Petri, M.

AU - Poque, B. C.

AU - Quinet, R. J.

AU - Ramsey-Goldman, R.

AU - Rosenblatt, S. G.

AU - Rothfield, N.

AU - Scarpa, N.

AU - Schneider, M.

AU - Schousboe, J. T.

AU - Sewell, L. K.

AU - Shergy, W. J.

AU - Sherrer, Y.

AU - Sibilia, J.

AU - Smith, D.

AU - Spinowitz, B.

AU - Spira, M.

AU - Staud, R.

AU - Stern, S.

AU - Stevens, M. P.

AU - Sturfelt, G.

AU - Surbeck, W.

AU - Tindall, E. A.

AU - Torres, A.

AU - Tumlin, J.

AU - Van Vollenhoven, R.

AU - Varga, J.

AU - Vijayan, A.

AU - Vilardell-Tarres, M.

AU - Wallace, D.

AU - Weaver, C.

AU - Zummer, M.

PY - 2005/4

Y1 - 2005/4

N2 - Objective. To examine the relationship between changes in anti-double-stranded DNA (anti-dsDNA) antibody levels and the risk of renal flare in patients with systemic lupus erythematosus (SLE), using data from 2 randomized, controlled trials. Methods. Analyses were based on 487 patients with SLE and a history of lupus nephritis who had an anti-dsDNA antibody titer ≥15 IU/ml at baseline, as measured by Farr assay. Results are presented for the combined population of patients, the placebo arms, and the drug treatment arms in which a dsDNA-based bioconjugate (abetimus sodium; LJP 394) was used. Results. Changes in anti-dsDNA antibody levels were inversely correlated with changes in the C3 level (P < 0.0001 in both trials). Cox proportional hazards regression models showed that changes in anti-dsDNA antibody levels correlated with the risk of renal flare. The models predicted that a point estimate of a 50% reduction in anti-dsDNA antibody levels is associated with a 52% reduction (95% confidence interval [95% CI] 26-68%, nominal P = 0.0007) and a 53% reduction (95% CI 33-69%, nominal P < 0.0001) in the risk of renal flare in the 2 trials, respectively. In the 2 trials, the incidence of renal flare was lower in patients with sustained reductions in anti-dsDNA antibodies (3.0% and 4.1%, respectively) than in patients with stable or increasing antibody levels (21.3% and 20.3%, respectively). Conclusion. Changes in anti-dsDNA antibody levels were directly correlated with the risk of renal flare and inversely correlated with changes in the C3 level. Reducing anti-dsDNA antibody levels may represent a therapeutic objective in SLE patients with lupus nephritis, because it is associated with a reduced risk of renal flare.

AB - Objective. To examine the relationship between changes in anti-double-stranded DNA (anti-dsDNA) antibody levels and the risk of renal flare in patients with systemic lupus erythematosus (SLE), using data from 2 randomized, controlled trials. Methods. Analyses were based on 487 patients with SLE and a history of lupus nephritis who had an anti-dsDNA antibody titer ≥15 IU/ml at baseline, as measured by Farr assay. Results are presented for the combined population of patients, the placebo arms, and the drug treatment arms in which a dsDNA-based bioconjugate (abetimus sodium; LJP 394) was used. Results. Changes in anti-dsDNA antibody levels were inversely correlated with changes in the C3 level (P < 0.0001 in both trials). Cox proportional hazards regression models showed that changes in anti-dsDNA antibody levels correlated with the risk of renal flare. The models predicted that a point estimate of a 50% reduction in anti-dsDNA antibody levels is associated with a 52% reduction (95% confidence interval [95% CI] 26-68%, nominal P = 0.0007) and a 53% reduction (95% CI 33-69%, nominal P < 0.0001) in the risk of renal flare in the 2 trials, respectively. In the 2 trials, the incidence of renal flare was lower in patients with sustained reductions in anti-dsDNA antibodies (3.0% and 4.1%, respectively) than in patients with stable or increasing antibody levels (21.3% and 20.3%, respectively). Conclusion. Changes in anti-dsDNA antibody levels were directly correlated with the risk of renal flare and inversely correlated with changes in the C3 level. Reducing anti-dsDNA antibody levels may represent a therapeutic objective in SLE patients with lupus nephritis, because it is associated with a reduced risk of renal flare.

UR - http://www.scopus.com/inward/record.url?scp=20244383590&partnerID=8YFLogxK

U2 - 10.1002/art.20980

DO - 10.1002/art.20980

M3 - Article

C2 - 15818711

AN - SCOPUS:20244383590

SN - 0004-3591

VL - 52

SP - 1129

EP - 1137

JO - Arthritis and rheumatism

JF - Arthritis and rheumatism

IS - 4

ER -

Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

Abstract

Access to Document

Other files and links

Fingerprint

Cite this